Resultado de búsqueda
11 de mar. de 2019 · The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.
1 de mar. de 2020 · The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.
Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.
2 de ago. de 2021 · Mechanisms of immediate HSRs to platins and taxanes. Phenotypes of platin HSRs include type I reactions, cytokine release reactions, and mixed reactions, with the most heterogeneity seen with oxaliplatin (A).
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy.
22 de may. de 2023 · Adverse Effects. Extravasation - If extravasation is suspected, the infusion should stop immediately. Any obvious fluid collection should be aspirated, and the extremity elevated. The antidote, sodium thiosulfate, should be administered.
15 de may. de 2018 · Other common side effects include anaphylaxis, cytopenias (including leukopenia and neutropenia, thrombocytopenia, and anaemia), hepatotoxicity, ototoxicity, cardiotoxicity, nausea and vomiting, diarrhea, mucositis, stomatitis, pain, alopecia, anorexia, cachexia, and asthenia.
